Grifols Stock Forum

$Grifols(GRFS.US)$ April 22, 2024 Grifols achieves positive results from phase 4 study of Fanhdi® (double-inactivated human anti-hemophilic factor) in patients with von Willebrand Disease Download PDF Grifols’ Fanhdi showed it could be effective, safe and well tolerated in the management of bleeding episodes and for the prevention of bleeding during surgeries in patients with von Willebrand Disease (VWD) VWD, which is caused by a deficiency of von Willebrand factor in plasma, is the most common ...

$Grifols(GRFS.US)$ Grifols (GRF.MC) is set to launch a private offering of 1 billion euros of 7.5% senior secured notes due April 2030 for the redemption of senior unsecured notes due May 2025.
The Spanish pharmaceutical group said Tuesday the note offering is contingent upon the fulfillment of customary closing conditions.

$Grifols(GRFS.US)$ International Medical Industries, Inc. Announces Partnership With Grifols for Enhanced Medication Safety!!! ((((( guess it may take some time to sink in ))))) Hehehe

$Grifols(GRFS.US)$ You know you wanna break out and up! Hehehe

$Grifols(GRFS.US)$ Grifols' Nucleic Acid Test for Arbovirus Detection Gets CE Marking
MT Newswires· 2 mins ago
Grifols (GRF.MC) said Thursday its automated nucleic acid test secured CE marking, representing the first for the medical device.
Procleix ArboPlex Assay is designed to screen blood donors to detect arboviruses diseases such as chikungunya, dengue, West Nile, and Zika viruses.
The Spanish pharmaceutical group said the test will soon be available worldwide to those accepting the CE...

$Grifols(GRFS.US)$ Hope the daily uptrend continues

RECAP
Treasury yields jumped on Thursday, and indexes fell after data showed a bigger-than-expected jump in producer prices during February, keeping inflation worries alive. The market reversed from larger declines shortly before closing.  
With the preliminary closing numbers, the $S&P 500 Index(.SPX.US)$ fell 0.29%, the $Dow Jones Industrial Average(.DJI.US)$ fell 0.35%, the $Nasdaq Composite Index(.IXIC.US)$...

$Grifols(GRFS.US)$ today announced positive topline results from AdFirst phase 3 study confirming the efficacy of fibrinogen concentrate in reducing intraoperative blood loss.

$Grifols(GRFS.US)$ very attractive at 9 - 9.50